Breaking News
December 15, 2018 - Tenacity and flexibility help maintain psychological well-being, mobility in older people
December 15, 2018 - Study reveals role of brain mechanism in memory recall
December 15, 2018 - High levels of oxygen encourage the brain to remain in deep, restorative sleep
December 15, 2018 - Experimental HIV vaccine strategy works in non-human primates, research shows
December 15, 2018 - Genetically modified pigs could limit replication of classical swine fever virus, study shows
December 15, 2018 - FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin
December 15, 2018 - Cost and weight-loss potential matter most to bariatric surgery patients
December 15, 2018 - Cancer Research UK and AstraZeneca open new Functional Genomics Centre
December 15, 2018 - New research lays out potential path for treatment of Huntington’s disease
December 15, 2018 - Prestigious R&D 100 Award presented to Leica Microsystems
December 15, 2018 - Study shows septin proteins detect and kill gut pathogen, Shigella
December 15, 2018 - Study sheds new light on disease-spreading mosquitoes
December 15, 2018 - 2017 Saw Slowing in National Health Care Spending
December 15, 2018 - Monitoring movement reflects efficacy of mandibular splint
December 15, 2018 - Study supports BMI as useful tool for assessing obesity and health
December 15, 2018 - Self-guided, internet-based therapy platforms effectively reduce depression
December 15, 2018 - Organically farmed food has bigger climate impact than conventional food production
December 15, 2018 - Faster, cheaper test has potential to enhance prostate cancer evaluation
December 15, 2018 - Researchers study abnormal blood glucose levels of patients after hospital discharge
December 15, 2018 - Swedish scientists explore direct association of dementia and ischemic stroke deaths
December 15, 2018 - Study finds 117% increase in number of dementia sufferers in 26 years
December 15, 2018 - Eczema Can Drive People to Thoughts of Suicide: Study
December 15, 2018 - Link between neonatal vitamin D deficiency and schizophrenia confirmed
December 15, 2018 - Nurse denied life insurance because she carries naloxone
December 15, 2018 - Ritalin drug affects organization of pathways that build brain networks used in attention, learning
December 15, 2018 - Research pinpoints two proteins involved in creation of stem cells
December 15, 2018 - Gut bacteria may modify effectiveness of anti-diabetes drugs
December 15, 2018 - How often pregnant women follow food avoidance strategy to prevent allergy in offspring?
December 15, 2018 - Using machine learning to predict risk of developing life-threatening infections
December 15, 2018 - How imaginary friends could boost children’s development
December 15, 2018 - Folate deficiency creates more damaging chromosomal abnormalities than previously known
December 15, 2018 - Study provides new insights into molecular mechanisms underlying role of amyloid in Alzheimer’s disease
December 15, 2018 - For the asking, a check is in the mail to help pay for costly drugs
December 15, 2018 - UA scientists uncover biological processes leading to rare brain disorder in babies
December 15, 2018 - The largest database on industrial poisons
December 15, 2018 - ESMO Immuno-Oncology Congress showcases novel technologies set to benefit many cancer patients
December 15, 2018 - Ovid Therapeutics Announces Plans to Move into a Phase 3 Trial in Pediatric Patients Based on End-of-Phase 2 Meeting for OV101 in Angelman Syndrome
December 15, 2018 - Left ventricular noncompaction – Genetics Home Reference
December 15, 2018 - Children’s sleep not significantly affected by screen time, new study finds
December 15, 2018 - When should dementia patients stop driving? A new guidance for clinicians
December 15, 2018 - Researchers use INTEGRA’s VIAFLO 96/384 to streamline the experimental workflow
December 15, 2018 - Researchers discover protein involved in nematode stress response
December 15, 2018 - Cancer patients have greater risk of developing shingles, study shows
December 14, 2018 - UAlberta scientists identify biomarkers for detecting Alzheimer’s disease in saliva samples
December 14, 2018 - Study uncovers link between tube travel and spread of flu-like illnesses
December 14, 2018 - Caffeine plus another compound in coffee may fight Parkinson’s disease
December 14, 2018 - GW researchers review studies on treatments for prurigo nodularis
December 14, 2018 - Lack of peds preventive care ups unplanned hospital admissions
December 14, 2018 - Miscarriage: When Language Deepens Pain
December 14, 2018 - New method helps better understand pathological development of ALS
December 14, 2018 - Intellectually active lifestyle confers protection against neurodegeneration in Huntington’s patients
December 14, 2018 - Mammalian collagen nanofibrils become stronger and tougher with exercise
December 14, 2018 - Considerable Morbidity, Mortality Due to Animal Encounters
December 14, 2018 - Researchers find inhibiting one protein destroys toxic clumps seen in Parkinson’s disease
December 14, 2018 - How early physical therapy can lessen the long-term need for opioids
December 14, 2018 - Depression, suicide rates highest in Mountain West states
December 14, 2018 - New model could cure the potential to underestimate how quickly diseases spread
December 14, 2018 - Exercise-induced hormone activates cells critical for bone remodeling in mice
December 14, 2018 - Researchers discover new mechanism behind spread of malignant pleural mesothelioma
December 14, 2018 - Health Tip: Celebrate a Healthier Holiday
December 14, 2018 - Scalpel-free surgery enhances quality of life for Parkinson’s patients, study finds
December 14, 2018 - Early physical therapy can reduce risk, amount of long-term opioid use | News Center
December 14, 2018 - Genetic marker, predictor of early relapse in common childhood cancer discovered
December 14, 2018 - Study could lead to a potential new way of treating sepsis
December 14, 2018 - New protein complex helps embryonic stem cells to maintain their indefinite potential
December 14, 2018 - Salk professor receives $1.8 million from NOMIS Foundation for research on mechanisms to promote health
December 14, 2018 - New discovery will improve the safety and predictability of CRISPR
December 14, 2018 - Geneticists discover how sex-linked disorders arise
December 14, 2018 - New method to visualize small-molecule interactions inside cells
December 14, 2018 - Study describes mechanism that makes people more vulnerable to hunger-causing stimuli
December 14, 2018 - Chronic opioid therapy associated with increased healthcare spending and hospital stays
December 14, 2018 - Blood Types
December 14, 2018 - Obesity linked to increased risk of early-onset colorectal cancer
December 14, 2018 - Blood test helps identify distinct molecular signatures in children with cystic fibrosis
December 14, 2018 - In California, doctors accused of sexual misconduct often get second chances
December 14, 2018 - Scientists use water to track electrical activity of nerve cells
December 14, 2018 - Recurrence of urinary tract infection may depend on bacterial strain, study shows
December 14, 2018 - GBT Announces U.S. FDA Agrees with its Proposal Relating to Accelerated Approval Pathway for Voxelotor for the Treatment of Sickle Cell Disease and GBT Plans to Submit New Drug Application (NDA)
December 14, 2018 - Partial Thromboplastin Time (PTT) Test: MedlinePlus Lab Test Information
December 14, 2018 - Common tactics for health promotion at work may be detrimental to employees with obesity
Tumor Cell Test Tops PSA for Survival in mCRPC

Tumor Cell Test Tops PSA for Survival in mCRPC

image_pdfDownload PDFimage_print

Action Points

  • Note that this analysis of data from 5 trials suggests that absence of circulating tumor cells performs better as a biomarker than change in PSA in terms of assessing response to therapy in metastatic, castration-resistant prostate cancer.
  • Be aware that the performance of this biomarker in clinical practice may be different than its performance in the context of a clinical trial.

Absence of circulating tumor cells (CTCs) after 13 weeks of treatment outperformed other potential markers of improved survival in patients with metastatic castration-resistant prostate cancer (mCRPC), a retrospective analysis of five randomized trials showed.

A decline in CTCs from nonzero at baseline to 0 at 13 weeks (CTC0) had a discriminatory power of 0.81 for predicting improved survival versus patients who did not achieve CTC0 status. The FDA-cleared response measure of CTC conversion (≥5 at baseline, ≤4 at 13 weeks) followed with a discriminatory power of 0.79. However, substantially more patients were evaluable for CTC0 than CTC conversion.

Six other response endpoints (CTC and PSA values) had discriminatory power ranging from 0.71 to 0.79, as reported online in the Journal of Clinical Oncology.

“The CTC0 endpoint is an indicator that cancer cells that were circulating in the blood are no longer detectable, an easily recognized outcome that is clinically meaningful to patients,” . “It is an outcome that occurs shortly after treatment initiation, providing researchers and practitioners with objective and reliable evidence that the therapy being administered had altered the patient’s prognosis in a favorable way.

“Taken together, the results of this study support the use of CTC0 as a response endpoint in early-phase clinical trials.”

The author of an accompanying editorial said that “the unambiguous interpretation of a positive and negative [CTC0] test should make this early efficacy marker an attractive intermediate endpoint for consideration of accelerated drug approval by regulatory bodies.”

“However, whether this endpoint should be used in routine clinical practice outside of a clinical trial (ie., as a measure of clinical benefit itself) is far less certain and seems premature at this time,” wrote Emanuel Antonarakis, MD, of Johns Hopkins University in Baltimore.

Antonarakis also acknowledged that PSA-based endpoints had less discriminatory power for predicting overall survival but pointed out that they could be evaluated in almost all patients across the five trials included in the analysis.

The need for clinically meaningful measures of response that occur early in the course of treatment for mCRPC has increased with the expansion of treatment options, including six new agents with diverse mechanisms of action approved since 2010. Each therapy’s approval was based on demonstration of a survival benefit in a large phase III trial, Scher and co-authors noted in their introduction.

In parallel with therapeutic expansion, advances in molecular profiling increased clinicians’ ability to identify subsets of patients and determine their likelihood of response to a given therapy. Historically, PSA-based tests were used to assess treatment efficacy, although the assessments did not provide a strong indication of survival, the authors continued.

In studies of mCRPC, patients with bone disease had higher numbers of CTCs compared with patients who have lymph node involvement, suggesting an association with metastatic spread. Inhibiting the spread of CTCs, therefore, should represent a clinically meaningful therapeutic objective, the authors continued. After phase II studies of abiraterone (Zytiga) and enzalutamide (Xtandi) showed CTC conversion rates of 30-40%, a research collaboration was formed in association with the FDA to study post-treatment CTC-based endpoints in phase III clinical trials.

Scher and colleagues reported findings from an analysis of short-term changes in CTC and PSA and their association with overall survival. The analysis comprised 6,081 patients with mCRPC from five prospective, randomized, phase III trials. Investigators examined the discriminatory power of CTC0 and CTC conversion at 13 weeks for identifying patients who would have improved survival. They also evaluated the endpoints of 30%, 50%, and 70% decreases in CTC count, as well as 30%, 50%, and 70% decreases in PSA level at 13 weeks.

To determine the discriminatory strength of each endpoint, investigators used assessment of the weighted c-index, which has a range of 0.5 to 1.0. A value of 0.5 reflected no discriminatory power between response and nonresponse, and a value of 1.0 indicated that almost all non-responding patients died before responding patients with the shortest survival. The analysis yielded the following discriminatory values:

  • CTC0: 0.81
  • CTC conversion: 0.79
  • CTC30: 0.72
  • CTC50: 0.72
  • CTC70: 0.73
  • PSA30: 0.71
  • PSA50: 0.72
  • PSA70: 0.74

The authors found that 75% of the patients could be evaluated for CTC0 compared with 51% for CTC conversion. As compared with a 70% decrease in PSA at 13 weeks, CTC0 offered significantly better discriminatory power (P=0.026) and, by extension, significantly better discrimination compared with PSA30 and PSA50.

“In addition to greater discrimination, the CTC0 and CTC conversion response endpoints were more robust, producing consistent weighted c-indices across the five trials,” the authors noted.

This work was partially supported by the FDA as part of a program to develop intermediate endpoints in castration-resistant prostate cancer. Some co-authors were employees of firms with commercial interests in such biomarkers.

Scher disclosed relationships with Asterias Biotherapeutics, Ferring Pharmaceuticals, WIRB-Copernicus Group, Merck, Clovis Oncology, Janssen Research & Development, Astellas Pharma, Sanofi, Physician’s Education Resource, OncLive Insights, Innocrin Pharmaceuticals, and Illumina.

Antonarakis disclosed relationships with Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Johnson & Johnson, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Tokai Pharmaceuticals, and patent/royalty/intellectual property interest.

  • Reviewed by
    F. Perry Wilson, MD, MSCE Assistant Professor, Section of Nephrology, Yale School of Medicine and Dorothy Caputo, MA, BSN, RN, Nurse Planner

2018-01-10T15:30:00-0500

Tagged with:

About author

Related Articles